Blueprint Medicines Corp (NASDAQ:BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today reported financial results and provided a business update for the fourth quarter and year ended December 31, 2015.
Recent Business Highlights
Platform and Pipeline:
- Initiated third Phase 1 clinical trial: In March 2016, Blueprint Medicines enrolled its first patient in its Phase 1 clinical trial of BLU-285 for the treatment of advanced systemic mastocytosis (SM).
- FDA granted orphan drug designation for BLU-285 for gastrointestinal stromal tumors (GIST) and SM: In January 2016, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to BLU-285 for the treatment of GIST and SM. Orphan drug designation may provide certain benefits, including a seven-year period of market exclusivity if the drug is approved, tax credits for qualified clinical trials and an exemption from FDA application fees.
- Presented preclinical data demonstrating anti-tumor activity of BLU-285 in models of acute myeloid leukemia (AML): In December 2015, at the 2015 American Society of Hematology (ASH) Annual Meeting, Blueprint Medicines presented new preclinical data demonstrating the potential utility of BLU-285 in a subset of patients with AML containing a mutation in KIT Exon 17. BLU-285 administration in a systemic model of AML driven by a KIT Exon 17 mutation resulted in tumor regression and reduced disease burden compared to cytarabine-treated animals. In addition, several mice treated with BLU-285 had undetectable disease after 24 days.
- Selected BLU-667 as development candidate for RET program: In December 2015,Blueprint Medicines selected BLU-667 as a development candidate for its RET program. RET is a receptor tyrosine kinase that can become abnormally activated by mutations or fusions. RET is a driver of disease in non-small cell lung cancer and cancers of the thyroid, and Blueprint Medicines’ research suggests that RET may be a driver of disease in subsets of colon and breast cancer. BLU-667 is an orally available, potent and selective inhibitor of RET and RET resistance mutations that Blueprint Medicines predicts will be found in patients. Blueprint Medicines plans to initiate 28-day Good Laboratory Practice toxicology studies for BLU-667 in the first half of 2016 with the goal of identifying the dose limiting toxicity and anticipated first-in-human dose for BLU-667.Blueprint Medicines plans to file an IND for BLU-667 by the end of 2016.
- Strengthened executive leadership team and board of directors: In January 2016,Blueprint Medicines announced the appointment of Kathryn (Kate) Haviland as Chief Business Officer and the promotion of Anthony (Andy) Boral, M.D., Ph.D., to Chief Medical Officer. In February 2016, Blueprint Medicines appointed Lonnel Coats to its board of directors.
- Launched Mast Cell Connect with PatientCrossroads: In December 2015, Blueprint Medicines and PatientCrossroads launched Mast Cell Connect, a patient registry sponsored by Blueprint Medicines to advance the understanding of mastocytosis and help speed the development of new therapies. Mast Cell Connect, the first-ever open-model registry for patients with mastocytosis, is designed to bring the medical community greater insights about the needs of people living with the disease and to enable patients to sign up to receive notifications of clinical trials and other research studies. In addition, Blueprint Medicines launched a systemic mastocytosis awareness website, “Together with Systemic Mastocytosis” at www.systemicmastocytosis.com.
Fourth Quarter and Full Year 2015 Financial Results
- Cash Position: As of December 31, 2015, cash and cash equivalents were $162.7 million, as compared to $47.2 million as of December 31, 2014. This increase was primarily due to net proceeds of $154.8 million received upon the closing of Blueprint Medicines’ initial public offering in May 2015. Blueprint Medicines expects that its existing cash and cash equivalents will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into at least the third quarter of 2017.
- Collaboration Revenue: Collaboration revenues were $4.6 million for the fourth quarter of 2015 and $11.4 million for the year ended December 31, 2015. Blueprint Medicines did not record any collaboration revenue during the same periods for 2014. The increase was due to Blueprint Medicines entering into a research, development and commercialization agreement with Alexion Pharma Holding (Alexion) in March 2015 to research, develop and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease. Collaboration revenues for the fourth quarter of 2015 and the year ended December 31, 2015 reflected reimbursement from Alexion for work conducted by Blueprint Medicines under the parties’ collaboration, as well as a portion of the $15.0 million upfront payment and a $1.8 million milestone payment, each of which will be amortized over the period of the research term, and a $0.3 million milestone payment, which was recognized upon achievement in December 2015.
- R&D Expenses: Research and development expenses were $16.4 million for the fourth quarter of 2015, as compared to $11.3 million for the same period in 2014. This increase was primarily attributable to approximately $1.8 million associated with buildingBlueprint Medicines’ platform and advancing its discovery pipeline forward, approximately $1.7 million in external clinical activities associated with advancingBlueprint Medicines’ two lead programs into clinical trials and approximately $1.5 millionin increased personnel expense. Research and development expenses were $48.6 millionfor the year ended December 31, 2015, as compared to $31.8 million for the year endedDecember 31, 2014. This increase was primarily attributable to approximately $6.0 million in increased personnel expense, approximately $6.0 million in external clinical activities associated with advancing Blueprint Medicines’ two lead programs into clinical trials, and approximately $5.4 million associated with building Blueprint Medicines’platform and advancing its discovery pipeline forward. These increases were partially offset by $0.7 million of lower expenses associated with external IND-enabling pre-clinical and toxicology studies as well as manufacturing activities.
- G&A Expenses: General and administrative expenses were $3.6 million for the fourth quarter of 2015, as compared to $3.0 million for the same period in 2014. This increase was primarily attributable to approximately $0.2 million in increased personnel costs and stock-based compensation expense and approximately $0.2 million in increased professional fees. General and administrative expenses were $14.5 million for the year ended December 31, 2015, as compared to $7.9 million for the year ended December 31, 2014. This increase was primarily attributable to approximately $3.5 million in increased personnel costs and stock-based compensation expense and approximately $2.5 millionin increased professional fees and fees paid to members of Blueprint Medicines’ board of directors.
- Net Loss: Net loss was $15.6 million for the fourth quarter of 2015, or a basic and diluted net loss per share available to common stockholders of $0.58, as compared to a net loss of $14.5 million for the same period in 2014, or a basic and diluted net loss per share available to common stockholders of $10.44. Net loss was $52.8 million for the year ended December 31, 2015, or a basic and diluted net loss per share available to common stockholders of $3.07, as compared to a net loss of $40.3 million for the year endedDecember 31, 2014, or a basic and diluted net loss per share available to common stockholders of $32.41. (Original Source)
Shares of Blueprint Medicines Corp. closed yesterday at $17, down $0.58 or -3.30%. BPMC has a 1-year high of $37.17 and a 1-year low of $13.04. The stock’s 50-day moving average is $16.75 and its 200-day moving average is $21.68.
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with genomically defined diseases driven by abnormal kinase activation.